Scitech Medical v. Cilag GmbH: São Paulo Appeal Reopens Patent Nullity Fight
Scitech Medical Products S.A. challenged the validity of Cilag GmbH International’s Brazilian patent BRPI0807365B1 — covering surgical instrument identification technology — before the Court of Justice of São Paulo. The appeal was granted, annulling the lower court judgment and ordering the evidentiary phase to be reopened so expert evidence on the patent’s nullity can be heard.
São Paulo court remands surgical instrument patent nullity for expert review
Scitech Medical Products S.A. brought proceedings against Cilag GmbH International before the Court of Justice of São Paulo (Case No. 1044824-18.2023.8.26.0100), asserting the incidental nullity of Brazilian patent BRPI0807365B1. The patent relates to surgical instrument identification technology, described in the case record as involving cryptographic and electrically-interchangeable-piece identification of surgical instruments — a field with significant implications for medical device interoperability and supply chain control.
The appeal was granted on 10 December 2025, with the appellate panel annulling the lower court’s judgment and ordering the case file returned to the court of origin. The specific basis for this outcome was that the first-instance court had not permitted expert evidence on the incidental nullity of the patent — a procedural gap the appellate court found warranted remand. The proceedings are to continue with the evidentiary phase reopened and an expert appointed to address pertinent questions on patent validity.
The remand to allow expert patent nullity evidence suggests the appellate court considered that technical examination of BRPI0807365B1’s validity was essential and had been improperly denied at first instance. The public record does not reveal what substantive invalidity arguments Scitech advanced, nor whether any infringement claims run in parallel. The outcome is procedural rather than substantive — no ruling on the patent’s validity has yet been made — meaning the core commercial and IP questions remain open.
Filing to Appeal Granted in 0 days
Case closed 10 December 2025 at appellate level in São Paulo
Appeal granted: what the São Paulo ruling means for both parties
Annulment and remand — no merits ruling yet
Granting the appeal and annulling the lower judgment means the first-instance decision has no legal force. The case is returned to the trial court, not to re-argue from scratch, but specifically to allow expert evidence on the incidental nullity of BRPI0807365B1. This is a procedural correction: the appellate court found the denial of expert evidence was an error that must be remedied before any substantive ruling can stand.
Remand — evidentiary phase reopenedScitech secures the right to challenge patent validity with expert evidence
Scitech Medical Products won a significant procedural victory: the appellate court agreed that it should have been allowed to present expert evidence on the nullity of BRPI0807365B1 at first instance. The remand gives Scitech the opportunity to build a technically substantiated invalidity case. Whether that case ultimately succeeds depends on the expert findings and the trial court’s subsequent merits decision.
Procedural win — nullity challenge preservedCilag faces renewed validity scrutiny at trial level
Cilag GmbH International’s patent BRPI0807365B1 now faces a formally reopened nullity challenge with court-appointed expert examination. The annulment of the lower judgment removes any procedural protection Cilag may have benefited from at first instance. Cilag will have the opportunity to submit counter-questions to the expert and contest any adverse technical findings, but the patent’s enforceability in Brazil remains uncertain until the merits are resolved.
Patent validity remains unresolvedSurgical instrument IP in Brazil: enforceability window narrows
For medical device companies operating in Brazil, this outcome signals that incidental patent nullity claims require proper evidentiary treatment — courts will not allow patent holders to avoid technical scrutiny by procedural default. Companies relying on BRPI0807365B1 for market exclusivity in surgical instrument identification should treat enforceability as provisional until the expert nullity proceedings conclude.
Brazilian patent enforceability at riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | SCITECH MEDICAL PRODUCTS S.A. | Individual | Medical device company — challenger of patent BRPI0807365B1 on incidental nullity groundsSearch in Eureka ↗ |
| Defendant | Cilag GMBH International | Company | Cilag GmbH International — subsidiary of Johnson & Johnson, holder of BRPI0807365B1Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The appellate panel’s language — ‘annul the judgment and order the return of the case file… for the reopening of the evidentiary phase’ — is unambiguously procedural: no substantive ruling on the validity of BRPI0807365B1 was made. The court’s grant of the appeal suggests it found the denial of expert evidence constituted a material procedural irregularity. For Scitech, the ruling preserves its nullity challenge intact. For Cilag, the patent remains formally in force but faces structured technical scrutiny before any merits judgment can be issued.
BRPI0807365B1 — Surgical instrument cryptographic identification system
BRPI0807365B1 is a granted Brazilian patent (publication number BRPI0807365B1) covering technology described in the case record as relating to the cryptographic and electrical identification of interchangeable surgical instrument pieces. The ‘PI 08’ designation indicates a PCT or foreign-origin application entering the Brazilian national phase around 2008. The technology sits at the intersection of surgical device engineering and digital security — addressing how surgical instruments authenticate or communicate component identity, which is relevant to surgical robotic and powered-instrument platforms.
Patents in this space typically protect competitive moats in premium surgical instrument ecosystems, where proprietary identification prevents third-party component substitution and supports recurring revenue from consumables. For Cilag GmbH International — a J&J subsidiary active in advanced surgical products — this patent is consistent with a portfolio strategy to lock in interoperability. The incidental nullity challenge by Scitech Medical suggests a direct commercial conflict: if BRPI0807365B1 is valid and infringed, it could exclude Scitech’s products from a segment of the Brazilian surgical instrument market.
Should you run an FTO analysis against BRPI0807365B1?
Any company developing, importing, or distributing surgical instruments with electronic or cryptographic component-identification features in Brazil should treat BRPI0807365B1 as a live risk — particularly while nullity proceedings are pending and no court has yet ruled the patent invalid. The patent’s scope in the cryptographic/electrical identification of interchangeable surgical pieces is broad enough to potentially capture instrument systems beyond the specific form factor originally filed.
PatSnap Eureka’s FTO Search Agent can map the claim scope of BRPI0807365B1 against your product specifications, identify related family members in other jurisdictions, and flag prosecution history estoppel that may limit or expand enforcement reach. Given the active nullity proceedings, Eureka can also surface any USPTO, EPO, or INPI office action history that may inform the expert phase — giving your legal team a strategic head start before the Brazilian trial court reconvenes.
Run a freedom-to-operate analysis on BRPI0807365B1 to assess your product’s exposure
Run FTO in Eureka →Similar surgical instrument and medical device patent nullity cases in Brazil
Cases involving incidental patent nullity challenges to medical device IP before Brazilian state courts and the Court of Justice of São Paulo, particularly in surgical instrument technology.
What this case signals for medical device patent IP in Brazil
This remand ruling highlights the procedural rigour Brazilian courts expect when patent nullity is raised incidentally in infringement or IP disputes.
Incidental nullity challenges in Brazil require expert evidence — courts will enforce this
The São Paulo appellate court’s decision to annul and remand confirms that Brazilian procedural law protects a defendant’s right to expert examination in incidental patent nullity proceedings. Companies defending against infringement claims — or asserting nullity offensively — should ensure expert evidence requests are formally on record and pursued at first instance to avoid procedural waiver.
BRPI0807365B1 enforceability is suspended in commercial terms pending expert review
Until the trial court completes the reopened evidentiary phase and issues a new merits judgment, the validity of BRPI0807365B1 is legally contested. Competitors and licensees in the surgical instrument identification space should monitor the remand proceedings closely — any expert finding on nullity will materially affect the patent’s licensing and enforcement value in Brazil.
S.A. v Cilag — key questions answered
The court granted Scitech’s appeal, annulled the lower court judgment, and ordered the case returned to the trial court to reopen the evidentiary phase. The specific purpose is to allow expert evidence on the incidental nullity of patent BRPI0807365B1. No ruling on the patent’s validity was made at this stage.
BRPI0807365B1 is a granted Brazilian patent held by Cilag GmbH International relating to the cryptographic and electrical identification of interchangeable surgical instrument components. The ‘PI 08’ prefix suggests it entered the Brazilian national phase around 2008, likely from a PCT filing. It covers technology relevant to surgical instrument authentication and interoperability systems.
In Brazilian procedural law, incidental nullity (nulidade incidental) allows a party in ongoing litigation to raise the invalidity of a patent as a defence or counterclaim within the same proceedings, rather than filing a separate administrative or judicial nullity action. The São Paulo appellate court confirmed that such a challenge entitles the raising party to expert evidence on the nullity question.
Formally, the patent remains in force — Brazilian courts do not typically suspend patent rights solely because a nullity challenge has been admitted. However, the commercial enforceability is contested: no court has yet ruled on validity, and the expert evidence phase ordered by the appellate court may produce findings that influence both the trial court’s merits decision and any parallel infringement proceedings.
The case file returns to the first-instance court of origin, which must reopen the evidentiary phase and appoint an expert to examine the nullity of BRPI0807365B1. Both parties will have the opportunity to submit questions for the expert. After the expert report is filed and contested, the trial court will issue a new merits judgment on the nullity question, which will again be subject to appeal.
PatSnap Eureka searches patents and litigation data to answer instantly.